Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 | BMJ

open here please ► full-text ▼
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 | BMJ

You can use bmj.com to help you with your continuing medical education. Find out about CME/CPD credits for BMJ articles

• 
  
• 
  
• 
  

Research

Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10

BMJ 2012; 344 doi: 10.1136/bmj.e2990 (Published 10 May 2012)

Cite this as: BMJ 2012;344:e2990

1. Øjvind Lidegaard, professor1,
2. Lars Hougaard Nielsen, statistician1,
3. Charlotte Wessel Skovlund, data manager1,
4. Ellen Løkkegaard, senior registrar2

Author Affiliations

1. Correspondence to: Ø Lidegaard Lidegaard@rh.regionh.dk

• Accepted 30 March 2012

Abstract

Objective To assess the risk of venous thrombosis in current users of non-oral hormonal contraception.

Design Historical national registry based cohort study.

Setting Four national registries in Denmark.

Participants All Danish non-pregnant women aged 15-49 (n=1 626 158), free of previous thrombotic disease or cancer, were followed from 2001 to 2010.

Main outcome measures Incidence rate of venous thrombosis in users of transdermal, vaginal, intrauterine, or subcutaneous hormonal contraception, relative risk of venous thrombosis compared with non-users, and rate ratios of venous thrombosis in current users of non-oral products compared with the standard reference oral contraceptive with levonorgestrel and 30-40 µg oestrogen. Diagnoses were confirmed by at least four weeks of anticoagulation therapy after the diagnosis.

Results Within 9 429 128 woman years of observation, 5287 first ever venous thrombosis events were recorded, of which 3434 were confirmed. In non-users of hormonal contraception the incidence rate of confirmed events was 2.1 per 10 000 woman years. Compared with non-users of hormonal contraception, and after adjustment for age, calendar year, and education, the relative risk of confirmed venous thrombosis in users of transdermal combined contraceptive patches was 7.9 (95% confidence interval 3.5 to 17.7) and of the vaginal ring was 6.5 (4.7 to 8.9). The corresponding incidences per 10 000 exposure years were 9.7 and 7.8 events. The relative risk was increased in women who used subcutaneous implants (1.4, 0.6 to 3.4) but not in those who used the levonorgestrel intrauterine system (0.6, 0.4 to 0.8). Compared with users of combined oral contraceptives containing levonorgestrel, the adjusted relative risk of venous thrombosis in users of transdermal patches was 2.3 (1.0 to 5.2) and of the vaginal ring was 1.9 (1.3 to 2.7).

Conclusion Women who use transdermal patches or vaginal rings for contraception have a 7.9 and 6.5 times increased risk of confirmed venous thrombosis compared with non-users of hormonal contraception of the same age, corresponding to 9.7 and 7.8 events per 10 000 exposure years. The risk was slightly increased in women using subcutaneous implants but not in those using the levonorgestrel intrauterine system.